Business
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate – The Motley Fool Australia
AstraZeneca PLC (LON: AZN) has revised its COVID-19 vaccine efficacy rating after concluding a more extensive study previously done.
Home / Coronavirus News / AstraZeneca COVID-19 vaccine trial data results in revised efficacy rateThe Oxford-AstraZeneca PLC (LON: AZN) COVID-19 vaccine has travelled a bumpy road through its development and rollout. Marred with accusations of the vaccine causing blood clots, regulatory and government pressures have weighed on the drug developer and its acceptance.
According to the latest press release from AstraZeneca, the company has revised the vaccine’s efficacy from 79% to 76%, following…
-
Noosa News14 hours agoPrincess Anne is coming to Australia. Here’s what we know of her plans
-
Noosa News23 hours agoCrystal Beale’s final moments revealed before her body was found in Brisbane River
-
General19 hours agoPolish woman found guilty of harassing Maddie McCann’s parents, but acquitted for stalking
-
General3 hours agoCommunity devastated after freight train kills one-year-old girl near Narrabri